Limited Scope of FDA Approval The most significant limitation is the narrow approved indication: FDA approval restricted exclusively to acquired, generalized hypoactive sexual desire disorder in premenopausal women No approved indication for men despite Phase 2 evidence of erectile dysfunction improvement No approval for postmenopausal women No approval for other forms of sexual dysfunction beyond HSDD All use outside this single indication represents off-label prescribing based on limited clinical trial data and physician clinical experience
It supports bone integrity, growth hormone regulation, glucose metabolism, and alleviates vasomotor symptoms
The specific patterns include: counterfeit products (contents not matching the label), compounded semaglutide from non-pharmacy sources (no batch quality control), telemedicine-only prescribing without adequate medical assessment, and absence of the contraindication screening and monitoring that proper clinical use requires
It's a poor fit if you have substantial weight to lose, because that's precisely what the full-dose programs are built and proven for, or if you're not willing to do the check-ins that stand in for the evidence nobody has published yet
And the emergence of GLP-1RA, such as semaglutide, exenatide, and efinopegdutide [116], and so on, can accelerate the drug development of NAFLD which has great therapeutic potential for the treatment of NAFLD [117]
The table says metformin works without requiring insulin secretion, while GLP-1 receptor agonists require functional beta cells for their glucose-dependent effect